AC Immune (ACIU) Change in Interest Receivables (2015 - 2023)
AC Immune (ACIU) posted quarterly Change in Interest Receivables of $259825.2 for Q3 2017, up 237.0% year-over-year from $77098.5 in Q3 2016, and up 146.8% quarter-over-quarter from -$555204.3 in Q2 2017.
AC Immune (ACIU) Change in Interest Receivables (2015 - 2023) Analysis & Trends
AC Immune (ACIU) has reported Change in Interest Receivables for 3 consecutive years, with $259825.2 the latest figure, recorded in Q3 2017.
- In Q3 2017, Change in Interest Receivables rose 237.0% year-over-year to $259825.2; the TTM figure through Sep 2017 stood at -$441832.4 (down 29.6% YoY), while the FY2016 annual figure was -$855069.2, down 13806.33% from the prior year.
- Change in Interest Receivables climbed to $259825.2 in Q3 2017 per ACIU's latest filing, from -$555204.3 in the prior quarter.
- Across five years, Change in Interest Receivables topped out at $355559.0 in Q1 2017 and bottomed at -$555204.3 in Q2 2017.
- Historically, Change in Interest Receivables has averaged -$97844.4 across 3 years, with a median of -$79174.7 in 2016.
- Annual changes were most pronounced in 2016 — Change in Interest Receivables tumbled 7196.86% — and 2017, when it soared 698.5%.
- AC Immune's Change in Interest Receivables stood at $7073.7 in 2015, then sank by 7196.86% to -$502012.3 in 2016, then soared by 151.76% to $259825.2 in 2017.
- Business Quant data shows ACIU's Change in Interest Receivables at $259825.2 in Q3 2017, -$555204.3 in Q2 2017, and $355559.0 in Q1 2017.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Interest Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | AC Immune | 253.89 Mn | 253.89 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2023 | 205,420.89 |
| Sep 30, 2022 | 401,757.17 |
| Jun 30, 2022 | -286,568.87 |
| Mar 31, 2022 | 896,565.34 |
| Sep 30, 2021 | 628,427.50 |
| Jun 30, 2021 | 65,798.83 |
| Mar 31, 2021 | 895,907.84 |
| Sep 30, 2020 | -565,996.42 |
| Jun 30, 2020 | -216,902.68 |
| Mar 31, 2020 | 910,818.85 |
| Sep 30, 2019 | -397,860.93 |
| Jun 30, 2019 | 265,283.90 |
| Mar 31, 2019 | 2.87 Mn |
| Sep 30, 2018 | 28,458.90 |
| Jun 30, 2018 | -1.51 Mn |
| Mar 31, 2018 | 1.74 Mn |
| Sep 30, 2017 | 259,825.22 |
| Jun 30, 2017 | -555,204.29 |
| Mar 31, 2017 | 355,558.96 |
| Dec 31, 2016 | -502,012.27 |